Sign in

NCT06261216Completed

Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

Source: ClinicalTrials.gov · Last updated 1 May 2026

Brief summary (registry, in English)

The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy.

Status (registry)
Completed
Study type
Observational
Enrollment
180 (actual)
First submitted
7 Feb 2024
Start date
16 Feb 2024
Primary completion date
20 Nov 2025
Lead sponsor
Medical University of Graz
Diseases
Amyloidosis
NCT number
NCT06261216

What you commit to

  • Study type: Observational
  • Participants enrolled: 180
  • From 16 Feb 2024 to the primary completion date, 20 Nov 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • History of severe chronic illness limiting the ability to perform physical activity during the 3rd to 6th decade
  • A diagnosis of dementia or cognitive impairment
  • Known disease-causing variant (pathogenic or likely-pathogenic) in the TTR gene
    • defined as an individual without one of the following diagnoses:
    • Cardiomyopathy of any origin, defined as a myocardial disorder with structural and functional abnormalities in the absence of coronary artery disease, hypertension, valvular disease, and congenital heart disease sufficient to cause the observed myocardial abnormality; or
    • Heart failure regardless of aetiology, defined as presence of distinct cardinal symptoms (e.g. breathlessness, ankle swelling, fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, peripheral oedema), due to a structural and/or functional abnormality of the heart, regardless of systolic function or aetiology; or
    • Clinically significant coronary artery disease, defined as 1) a history of coronary intervention; or 2) inducible myocardial ischemia and ischaemic chest pain (angina pectoris) due to flow-limiting stenoses, diffuse atherosclerotic lesions, structural abnormalities, congenital anomalies, dynamic epicardial vasospasm; or
    • Clinically significant valvular heart disease, defined as 1) a history of valvular surgery or intervention; or 2) moderate or severe stenosis or regurgitation; or
    • Hypertrophic phenotype defined as enddiastolic maximal wall thickness ≥ 15mm; or
    • History of arrhythmias or significant conduction disease, defined as ventricular brady- or tachyarrhythmias, atrial flutter or atrial fibrillation, sick sinus syndrome, or atrioventricular block greater than 1st degree block; or
    • History of sudden cardiac arrest, defined as sudden cessation of normal cardiac activity with haemodynamic collapse

Other

  • Any other reason resulting in the inability to perform the questionnaire and/or interview

Who the study is looking for

  • Confirmed diagnosis of wtATTR-CM including sequencing of the TTR gene; or HF; or healthy proband without a diagnosis of heart disease\*
  • Initial diagnosis of respective cardiac disease (wtATTR-CM, HF) after the 6th decade of life; or no cardiac disease (healthy control)
  • Willingness and ability to provide signed informed consent form (ICF)
  • Age \> 60 years

Age in the registry: 60 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Medical University of Graz
Coordinator of this site? Confirm its status
GrazAustriaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.